A retrospective cohort study of biosimilar rituximab therapy in pemphigus: experience from a tertiary care hospital in North India

A retrospective cohort study of biosimilar rituximab therapy in pemphigus: experience from a tertiary care hospital in North India

Saved in:

Bibliographic Details
Main Authors:	Sabha Mushtaq, Devraj Dogra, Naina Dogra
Format:	Article
Language:	English
Published:	Termedia Publishing House 2024-11-01
Series:	Przegląd Dermatologiczny
Subjects:	pemphigus biosimilar rituximab dexamethasone cyclophosphamide pulse glucocorticosteroids remission relapse
Online Access:	https://www.termedia.pl/A-retrospective-cohort-study-of-biosimilar-rituximab-therapy-in-pemphigus-experience-from-a-tertiary-care-hospital-in-North-India,56,55056,1,1.html
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exploration of rituximab treatment strategies for membranous nephropathy adapted to the Chinese healthcare environment
by: Xiaolong Wang, et al.
Published: (2025-01-01)

Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris
by: Tal Raviv, et al.
Published: (2025-01-01)

CURRENT APPROACH TO DEVELOPMENT OF BIOSIMILAR PRODUCTS CONTAINING MONOCLONAL ANTIBODIES AS AN ACTIVE SUBSTANCE – NON-CLINICAL AND CLINICAL STUDIES OF THE FIRST RUSSIAN RITUXIMAB BIOSIMILAR, ACELLBIA®
by: S. M. Alekseev, et al.
Published: (2015-04-01)

Review of modern techniques and analysis of patient outcomes with benign familial pemphigus Gougereau–Haley–Haley
by: Marianna B. Drozhdina, et al.
Published: (2024-12-01)

Evaluation of the Effects of systemic Therapy on Inflammatory Markers and Disease Severity in Patients With Pemphigus
by: Mehmet Enes Güner, et al.
Published: (2025-01-01)

Consensus Based Indian Guidelines for the Management of Pemphigus Vulgaris and Pemphigus Foliaceous
by: Dipankar De, et al.
Published: (2025-01-01)

Persistent Nasal Skin Lesions in Pemphigus Patients and the Role of Methotrexate in Treatment: A Case Series Study
by: Mohamad Reza Kavyani, et al.
Published: (2025-01-01)

Comparison of rituximab vs. cyclophosphamide in rheumatoid arthritis-associated interstitial lung disease and its correlation with spirometry
by: Mohammed Abdullah Saleem, et al.
Published: (2024-12-01)

Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India
by: Keerthi Talari, et al.
Published: (2021-01-01)

The utilization of the multimodal immunotherapy for the opsoclonus–myoclonus syndrome can reduce relapses and permanent neurological sequelae
by: Fang He, et al.
Published: (2025-02-01)

The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis
by: Magdalena Kaniewska, et al.
Published: (2017-09-01)

Inferior Outcomes of Fludarabine–Cyclophosphamide–Rituximab Chemotherapy in Korean Chronic Lymphocytic Leukemia Patients with Concurrent Thrombocytopenia and Anemia
by: Tong-Yoon Kim, et al.
Published: (2025-01-01)

Life-threatening Pneumocystis jiroveci Pneumonia with Cytomegalovirus Coinfection in a Follicular Lymphoma Patient During Rituximab-based Chemotherapy
by: Mu-Chun Yang, et al.
Published: (2024-01-01)

The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease
by: P. Rutgeerts
Published: (1998-01-01)

Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
by: Mohammed Alqahtani, et al.
Published: (2024-11-01)

Kinetic-pharmacodynamic model to predict post-rituximab B-cell repletion as a predictor of relapse in pediatric idiopathic nephrotic syndrome
by: Ziwei Li, et al.
Published: (2025-01-01)

Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis
by: Arun Hegde, et al.
Published: (2018-01-01)

Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study
by: Chie Ogita, et al.
Published: (2025-01-01)

Immunosuppressive therapy of patients with pemphigus with ineffectiveness of systemic corticosteroids
by: Vadim V. Chikin, et al.
Published: (2024-12-01)

Knowledge on the Use of Biosimilars in Hematological Malignancies Amongst Health Care Workers at a Tertiary Hospital in Northeast Nigeria
by: Rufai A. Dachi, et al.
Published: (2024-07-01)

The impact of signaling pathways on the desmosome ultrastructure in pemphigus
by: Thomas Schmitt, et al.
Published: (2025-01-01)

The Impact of Air Pollution on Disease Activity in Bullous Pemphigoid and Pemphigus
by: Ron Feldman, et al.
Published: (2025-05-01)

Two Patients with Therapy-Resistant Pemphigus Vulgaris and Severe Underlying Disease Showing Good Response to a New IVIg Preparation
by: Katharina Hogrefe, et al.
Published: (2025-01-01)

Rituximab-induced serum sickness: Not so uncommon
by: Vikramraj K Jain
Published: (2018-01-01)

Direct immunofluorescence (DIF) versus immunohistochemical (IHC) staining of complements and immunoglobulins (Ig) in pemphigus group
by: Deepika Rana, et al.
Published: (2024-04-01)

Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study
by: Debdulal Chakraborty, et al.
Published: (2025-01-01)

A comprehensive, population level evaluation of previously reported drug triggers of pemphigus highlights immunomodulatory capacity as a common characteristic
by: Justin Baroukhian, et al.
Published: (2025-01-01)

Case report: A rollercoaster journey of pemphigus vegetans
by: Xiaoyuan Hou, et al.
Published: (2025-01-01)

Paraneoplastic pemphigus involved oral mucosa only: a case report and literature review
by: Xixi Yu, et al.
Published: (2025-01-01)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
by: Magdalena Kaniewska, et al.
Published: (2019-12-01)

Biologics in ocular inflammatory diseases – Experience from a tertiary referral eye care center in South India
by: Kalpana Babu, et al.
Published: (2025-02-01)

Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product
by: Neungseon Seo, et al.
Published: (2024-11-01)

Healthy individuals genetically at-risk for the development of Pemphigus vulgaris or Alopecia areata share disease-like cytokine dysregulation
by: Rebekah R. Schwartz, et al.
Published: (2025-01-01)

Immunological Remission as a Basis for Dose Reduction of Immunosuppressors in Autoimmune Hepatitis: Results of Monocenter Surveillance Study
by: A. O. Bueverov, et al.
Published: (2024-03-01)

Transition of Thyroid Autoantibodies by Rituximab Treatment in Women with Rheumatoid Arthritis
by: Hüseyin Demirci, et al.
Published: (2024-10-01)

The effectiveness of dexamethasone as a combination therapy for COVID-19
by: Namazi Nader
Published: (2022-09-01)

Rituximab in Refractory Myasthenia Gravis – Challenges and Lessons Learnt
by: Karthika A Valaparambil, et al.
Published: (2024-12-01)

Effects of infliximab biosimilar on retinal microvasculature in Crohn’s disease patients evaluated by optical coherence tomography angiography
by: Hesham M. El Mazar, et al.
Published: (2025-01-01)

IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?
by: S. V. Orlov, et al.
Published: (2016-06-01)

Biosimilars in Focus: Evaluating Their Role Compared to Adalimumab in Clinical Practice
by: Dorota Waz, et al.
Published: (2025-01-01)